Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.
Former Fierce 15 winner MaxQ plans to go public with $8 million IPO, as it awaits FDA approval of its AI tech for analyzing CT scans for brain bleeds.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Senseonics’ long-term CGM is now available in clinics across the U.S. and has secured its first commercial payer.
Akili brought its series C total up to $68 million while it awaits an FDA decision on its prescription video game for pediatric ADHD.
Siemens Healthineers tapped NuVasive as a partner in minimally invasive spine surgery, integrating surgical automation platforms with 3D imaging.
Agilent’s PD-L1 assay was expanded in Europe to help guide first-line Keytruda treatment in urothelial carcinoma.
Boston Scientific is acquiring the remainder of Veniti for $108 million upfront, plus up to $52 million pending approval of its Vici venous stent.
Credence MedSystems received a shot of $12.8 million in financing through a series B round.
Sensyne Health plans to go public with a £60 million listing ($77 million) on the London Stock Exchange on Aug. 17.
Certara said its software supported 95% of the 20 novel FDA approvals from the first half of this year, as the agency aims to modernize its reviews.